Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
CVC, GBL transfer 12.428% Recordati stake to Respighi BidCo

CVC, GBL transfer 12.428% Recordati stake to Respighi BidCo

BitgetBitget2026/11/07 21:31
  • CVC and GBL contributed a combined 12.43% stake in Recordati to Respighi BidCo on November 2, 2026.
  • Respighi BidCo held 155,966,684 shares, representing 74.58% of the capital, as of November 6.
  • Including additional tender acceptances and treasury shares, Respighi BidCo and CVC's combined holding would reach 86.26% as of November 6.
  • The reopened offer period runs from November 3 through November 9, 2026.
  • Respighi BidCo plans a squeeze-out if ownership reaches 90%; below that threshold, delisting would proceed through a merger, subject to corporate approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recordati Industria Chimica e Farmaceutica S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 216_173433_2026_oneinfo.pdf), on November 07, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss